Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVE0657 in Cheyne-Stokes Breathing Syndrome
NCT00694720Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jun 2008
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of AVE-0657 in Cheyne-Stokes respiration (CSR), sponsored by Sanofi. Primary endpoint: Change in the Apnea Hypopnea Index at 2 days. Started Jun 2008; status: terminated.
02
Drugs
AVE-0657
03
Conditions
Cheyne-Stokes respiration (CSR)
Beyond the preview
Go deeper on NCT00694720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00694720.